taranabant

Small moleculeexperimental

Taranabant (codenamed MK-0364) is a cannabinoid receptor type 1 (CB1) inverse agonist that was investigated as a potential treatment for obesity due to its anorectic effects. It was developed by Merck & Co. — Wikipedia

Clinical trial activity

9 trials · 1 clinical orgs · 0 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Jul 1, 2004 (NCT00109148)

Timeline

2000s

Jan 1, 2004
Earliest Phase 2 Sponsor(trial)
Jan 1, 2005
Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Cannabinoid CB1 receptorINVERSE AGONIST
CNR1 inverse agonist
Merck has Discontinueddevelopment of the drug, potential serious side effects linked to targetting of CNR1 (http://en.wikipedia.org/wiki/Taranabant)
- Cannabinoid receptor 1 (CNR1) ↗

Chemistry & pharmacology

Loading structure…

SMILES

C[C@H](NC(=O)C(C)(C)Oc1ccc(C(F)(F)F)cn1)[C@@H](Cc1ccc(Cl)cc1)c1cccc(C#N)c1

Mol. weight: 515.96 g/mol
Lipinski Ro5: 2 violation(s)
Rule of 3: No
Chirality: Single Stereoisomer
Inorganic: No
Polymer: No

Oral

Parenteral

Topical

Sources

WikipediaTaranabant ↗
ChEMBLCHEMBL220360 ↗

Also known as

mk0364
mk0364
mk0364
mk 0364
mk-0364
mk-0364
mk-0364
mk-0634
mk-0634
mk-0634
n-(3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl)-2-methyl-2-((5-(trifluoromethyl)pyridin-2-yl)oxy)propanamide
taranabant
taranabant
taranabant
taranabant

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT00430742	Phase 3	Nov 1, 2006	Merck
NCT00384605	Phase 3	Oct 1, 2006	Merck
NCT00420589	Phase 3	Oct 1, 2006	Merck
NCT00131404	Phase 3	Sep 1, 2005	Merck
NCT00131430	Phase 2/Phase 3 (Phase 3)	Aug 1, 2005	Merck
NCT00231790	Phase 2	Aug 1, 2005	Merck
NCT00131391	Phase 3	Jul 1, 2005	Merck
NCT00109135	Phase 2	Jan 1, 2005	Merck
NCT00109148	Phase 2	Jul 1, 2004	Merck

Showing 9 of 9 trials

Page 1 / 1

Organizations

Research & Development (1)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Merck	For profit	9	9	2	2004

1 organizations

Page 1 / 1